I have been holding a couple thousand shares since 2009, and want to get an idea of the value of the stock assuming the NDA is approved. Can I get a few responses from other contributors, preferably with some reasoned explanation of the estimates. Thanks
Bob, I think it's reasonable to assume that the upside could be significant. The approval payment from Alimera will be 25MIL. The Pfizer payment of 2.3 MIL will also be visible this quarter on the Latanoprost deal. The profit sharing from Illuvien of 20% should represent significant revenue for several years going forward. This should more than put PSDV in the black. If we assume a 14 P/E multiple, perhaps the PPS could be in the mid teens or higher. If the new platform gets approved....the sky will be the limit. They would be a huge takeover target. I'm very bullish.